Skandinaviska Enskilda Banken AB publ Trims Stock Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)

Skandinaviska Enskilda Banken AB publ decreased its position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 67.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 189,472 shares of the company's stock after selling 394,017 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned 0.08% of Sana Biotechnology worth $305,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB purchased a new stake in Sana Biotechnology in the third quarter valued at $29,000. Blue Trust Inc. lifted its holdings in shares of Sana Biotechnology by 51.0% in the 4th quarter. Blue Trust Inc. now owns 19,823 shares of the company's stock valued at $32,000 after buying an additional 6,694 shares during the period. Ieq Capital LLC purchased a new stake in shares of Sana Biotechnology in the fourth quarter worth about $32,000. Stifel Financial Corp acquired a new stake in Sana Biotechnology during the third quarter worth about $43,000. Finally, EP Wealth Advisors LLC acquired a new stake in Sana Biotechnology during the third quarter worth about $45,000. Hedge funds and other institutional investors own 88.23% of the company's stock.

Sana Biotechnology Price Performance

NASDAQ SANA traded up $0.05 on Friday, hitting $2.31. The company had a trading volume of 4,922,585 shares, compared to its average volume of 3,044,006. The company's fifty day moving average price is $2.98 and its 200-day moving average price is $3.19. The company has a market capitalization of $519.81 million, a PE ratio of -1.65 and a beta of 1.63. Sana Biotechnology, Inc. has a 12-month low of $1.52 and a 12-month high of $10.50.

Remove Ads

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its earnings results on Monday, March 17th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02. On average, sell-side analysts anticipate that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

Wall Street Analysts Forecast Growth

SANA has been the subject of a number of analyst reports. HC Wainwright reissued a "buy" rating and issued a $11.00 price target on shares of Sana Biotechnology in a report on Tuesday. Citizens Jmp upgraded shares of Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 target price for the company in a research note on Tuesday. TD Cowen upgraded shares of Sana Biotechnology from a "hold" rating to a "buy" rating in a research report on Wednesday, January 8th. Finally, Jefferies Financial Group started coverage on shares of Sana Biotechnology in a report on Friday, March 14th. They issued a "buy" rating and a $7.00 price objective for the company. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, Sana Biotechnology currently has an average rating of "Moderate Buy" and an average target price of $10.80.

Insider Activity

In other Sana Biotechnology news, insider Fmr Llc sold 290,912 shares of the business's stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the transaction, the insider now owns 4,541,511 shares of the company's stock, valued at approximately $29,474,406.39. The trade was a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 31.10% of the company's stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.